Plasma-to-tumour tissue integrated proteomics using nano-omics for biomarker discovery in glioblastoma

Xinming Liu, Hanan Abmanhal-Masarweh, Olivia Iwanowytsch, Emmanuel Okwelogu, Kiana Arashvand, Konstantina Karabatsou, Pietro Ivo D’Urso, Federico Roncaroli, Kostas Kostarelos, Thomas Kisby () and Marilena Hadjidemetriou ()
Additional contact information
Xinming Liu: The University of Manchester
Hanan Abmanhal-Masarweh: The University of Manchester
Olivia Iwanowytsch: The University of Manchester
Emmanuel Okwelogu: The University of Manchester
Kiana Arashvand: University of Manchester
Konstantina Karabatsou: Salford Royal NHS Foundation Trust
Pietro Ivo D’Urso: Salford Royal NHS Foundation Trust
Federico Roncaroli: The University of Manchester
Kostas Kostarelos: The University of Manchester
Thomas Kisby: University of Manchester
Marilena Hadjidemetriou: The University of Manchester

Nature Communications, 2025, vol. 16, issue 1, 1-14

Abstract: Abstract Glioblastoma (GB) is the most lethal brain cancer, with patient survival rates remaining largely unchanged over the past two decades. Here, we introduce the Nano-omics integrative workflow that links systemic (plasma) and localised (tumour tissue) protein changes associated with GB progression. Mass spectrometry analysis of the nanoparticle biomolecule corona in GL261-bearing mice at different stages of GB revealed plasma protein alterations, even at low tumour burden, with over 30% overlap between GB-specific plasma and tumour tissue proteomes. Analysis of matched plasma and surgically resected tumour samples from high-grade glioma patients demonstrates the clinical applicability of the Nano-omics pipeline. Cross-species correlation identified 48 potential GB biomarker candidates involved in actin cytoskeleton organisation, focal adhesion, platelet activation, leukocyte migration, amino acid biosynthesis, carbon metabolism, and phagosome pathways. The Nano-omics approach holds promise for the discovery of early detection and disease monitoring biomarkers of central nervous system conditions, paving the way for subsequent clinical validation.

Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-58252-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-58252-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-58252-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().